In this regard, we recently demonstrated an efficient CXCR2 antagonization with SB225002 (SB) with a significantly reduced tumor volume, decreased vessel density, and reduced TAM infiltration in an in vivo GL261 syngeneic mouse model [6,7,8,9,10]. Here, CXCR2 is linked to neoplasm.